Cargando…

Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration

(1) Objectives: to describe the pharmacokinetic/pharmacodynamic (PK/PD) profile of continuous infusion (CI) meropenem in critical patients with documented Gram-negative infections undergoing continuous veno-venous hemodiafiltration (CVVHDF) and to assess the relationship with microbiological outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatti, Milo, Rinaldi, Matteo, Tonetti, Tommaso, Siniscalchi, Antonio, Viale, Pierluigi, Pea, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604776/
https://www.ncbi.nlm.nih.gov/pubmed/37887225
http://dx.doi.org/10.3390/antibiotics12101524
_version_ 1785126916105175040
author Gatti, Milo
Rinaldi, Matteo
Tonetti, Tommaso
Siniscalchi, Antonio
Viale, Pierluigi
Pea, Federico
author_facet Gatti, Milo
Rinaldi, Matteo
Tonetti, Tommaso
Siniscalchi, Antonio
Viale, Pierluigi
Pea, Federico
author_sort Gatti, Milo
collection PubMed
description (1) Objectives: to describe the pharmacokinetic/pharmacodynamic (PK/PD) profile of continuous infusion (CI) meropenem in critical patients with documented Gram-negative infections undergoing continuous veno-venous hemodiafiltration (CVVHDF) and to assess the relationship with microbiological outcome. (2) Methods: Data were retrospectively retrieved for patients admitted to the general and the post-transplant intensive care units in the period October 2022–May 2023 who underwent CVVHDF during treatment with CI meropenem optimized by means of a real-time therapeutic drug monitoring (TDM)-based expert clinical pharmacological advice (ECPA) program for documented Gram-negative infections. Steady-state meropenem plasma concentrations were measured, and the free fractions (fC(ss)) were calculated. Meropenem total clearance (CL(tot)) was calculated at each TDM assessment, and the impact of CVVHDF dose intensity and of residual diuresis on CL(tot) was investigated by means of linear regression. Optimal meropenem PK/PD target attainment was defined as an fC(ss)/MIC ratio > 4. The relationship between meropenem PK/PD target attainment and microbiological outcome was assessed. (3) Results: A total of 24 critical patients (median age 68 years; male 62.5%) with documented Gram-negative infections were included. Median (IQR) meropenem fC(ss) was 19.9 mg/L (17.4–28.0 mg/L). Median (IQR) CL(tot) was 3.89 L/h (3.28–5.29 L/h), and median (IQR) CVVHDF dose intensity was 37.4 mL/kg/h (33.8–44.6 mL/kg/h). Meropenem dosing adjustments were provided in 20 out of 24 first TDM assessments (83.3%, all decreases) and overall in 26 out of the 51 total ECPA cases (51.0%). Meropenem PK/PD target attainment was always optimal, and microbiological eradication was achieved in 90.5% of assessable cases. (4) Conclusion: the real-time TDM-guided ECPA program was useful in attaining aggressive PK/PD targeting with CI meropenem in critically ill patients undergoing high-intensity CVVHDF and allowed microbiological eradication in most cases with dosing regimens ranging between 125 and 500 mg q6h over 6 h.
format Online
Article
Text
id pubmed-10604776
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106047762023-10-28 Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration Gatti, Milo Rinaldi, Matteo Tonetti, Tommaso Siniscalchi, Antonio Viale, Pierluigi Pea, Federico Antibiotics (Basel) Article (1) Objectives: to describe the pharmacokinetic/pharmacodynamic (PK/PD) profile of continuous infusion (CI) meropenem in critical patients with documented Gram-negative infections undergoing continuous veno-venous hemodiafiltration (CVVHDF) and to assess the relationship with microbiological outcome. (2) Methods: Data were retrospectively retrieved for patients admitted to the general and the post-transplant intensive care units in the period October 2022–May 2023 who underwent CVVHDF during treatment with CI meropenem optimized by means of a real-time therapeutic drug monitoring (TDM)-based expert clinical pharmacological advice (ECPA) program for documented Gram-negative infections. Steady-state meropenem plasma concentrations were measured, and the free fractions (fC(ss)) were calculated. Meropenem total clearance (CL(tot)) was calculated at each TDM assessment, and the impact of CVVHDF dose intensity and of residual diuresis on CL(tot) was investigated by means of linear regression. Optimal meropenem PK/PD target attainment was defined as an fC(ss)/MIC ratio > 4. The relationship between meropenem PK/PD target attainment and microbiological outcome was assessed. (3) Results: A total of 24 critical patients (median age 68 years; male 62.5%) with documented Gram-negative infections were included. Median (IQR) meropenem fC(ss) was 19.9 mg/L (17.4–28.0 mg/L). Median (IQR) CL(tot) was 3.89 L/h (3.28–5.29 L/h), and median (IQR) CVVHDF dose intensity was 37.4 mL/kg/h (33.8–44.6 mL/kg/h). Meropenem dosing adjustments were provided in 20 out of 24 first TDM assessments (83.3%, all decreases) and overall in 26 out of the 51 total ECPA cases (51.0%). Meropenem PK/PD target attainment was always optimal, and microbiological eradication was achieved in 90.5% of assessable cases. (4) Conclusion: the real-time TDM-guided ECPA program was useful in attaining aggressive PK/PD targeting with CI meropenem in critically ill patients undergoing high-intensity CVVHDF and allowed microbiological eradication in most cases with dosing regimens ranging between 125 and 500 mg q6h over 6 h. MDPI 2023-10-10 /pmc/articles/PMC10604776/ /pubmed/37887225 http://dx.doi.org/10.3390/antibiotics12101524 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gatti, Milo
Rinaldi, Matteo
Tonetti, Tommaso
Siniscalchi, Antonio
Viale, Pierluigi
Pea, Federico
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
title Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
title_full Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
title_fullStr Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
title_full_unstemmed Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
title_short Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
title_sort real-time tdm-based expert clinical pharmacological advice program for attaining aggressive pharmacokinetic/pharmacodynamic target of continuous infusion meropenem in the treatment of critically ill patients with documented gram-negative infections undergoing continuous veno-venous hemodiafiltration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604776/
https://www.ncbi.nlm.nih.gov/pubmed/37887225
http://dx.doi.org/10.3390/antibiotics12101524
work_keys_str_mv AT gattimilo realtimetdmbasedexpertclinicalpharmacologicaladviceprogramforattainingaggressivepharmacokineticpharmacodynamictargetofcontinuousinfusionmeropeneminthetreatmentofcriticallyillpatientswithdocumentedgramnegativeinfectionsundergoingcontinuousvenovenoushemodia
AT rinaldimatteo realtimetdmbasedexpertclinicalpharmacologicaladviceprogramforattainingaggressivepharmacokineticpharmacodynamictargetofcontinuousinfusionmeropeneminthetreatmentofcriticallyillpatientswithdocumentedgramnegativeinfectionsundergoingcontinuousvenovenoushemodia
AT tonettitommaso realtimetdmbasedexpertclinicalpharmacologicaladviceprogramforattainingaggressivepharmacokineticpharmacodynamictargetofcontinuousinfusionmeropeneminthetreatmentofcriticallyillpatientswithdocumentedgramnegativeinfectionsundergoingcontinuousvenovenoushemodia
AT siniscalchiantonio realtimetdmbasedexpertclinicalpharmacologicaladviceprogramforattainingaggressivepharmacokineticpharmacodynamictargetofcontinuousinfusionmeropeneminthetreatmentofcriticallyillpatientswithdocumentedgramnegativeinfectionsundergoingcontinuousvenovenoushemodia
AT vialepierluigi realtimetdmbasedexpertclinicalpharmacologicaladviceprogramforattainingaggressivepharmacokineticpharmacodynamictargetofcontinuousinfusionmeropeneminthetreatmentofcriticallyillpatientswithdocumentedgramnegativeinfectionsundergoingcontinuousvenovenoushemodia
AT peafederico realtimetdmbasedexpertclinicalpharmacologicaladviceprogramforattainingaggressivepharmacokineticpharmacodynamictargetofcontinuousinfusionmeropeneminthetreatmentofcriticallyillpatientswithdocumentedgramnegativeinfectionsundergoingcontinuousvenovenoushemodia